EP4686470A1 — Macrocyclic peptidomimetics as antiviral agents
Assigned to Ospedale San Raffaele SRL · Expires 2026-02-04 · 0y expired
What this patent protects
The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M pro with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M pro associated or mediated diseases and conditions, su…
USPTO Abstract
The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M pro with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M pro associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).
Drugs covered by this patent
- Paxlovid (Copackaged) (Nirmatrelvir) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.